WASHINGTON (Reuters) - U.S. drug reviewers have questioned Pfizer Inc.'s data showing the pain reliever Celebrex was as effective as an older drug in treating juvenile rheumatoid arthritis, a summary ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results